Baxalta, on cusp of buyout, bags cancer drug deal with Onconova

Baxalta ($BXLT), soon to be part of Shire ($SHPG), has decided to bag its $565 million cancer partnership for Onconova Therapeutics' ($ONTX) twice-failed treatment for myelodysplastic syndrome, a rare bone marrow disorder that often develops after patients receive cancer therapy. The deal had been struck in 2012, when Baxalta was part of Baxter ($BAX), but the company has decided it no longer fits into its "strategic priorities." In January, Baxalta succumbed to Shire's $32 billion buyout offer. The deal is expected to close this summer. More from FierceBiotech

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.